| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6635234 | BAYER HLTHCARE | Preparation and use of radium-223 to target calcified tissues for pain palliation, bone cancer therapy, and bone surface conditioning |
Nov, 2022
(1 year, 5 months ago) | |
| US8791127 | BAYER HLTHCARE | Mucosal bioadhesive slow release carrier for delivering active principles |
Mar, 2027
(2 years from now) | |
Xofigo is owned by Bayer Hlthcare.
Xofigo contains Radium Ra-223 Dichloride.
Xofigo has a total of 2 drug patents out of which 1 drug patent has expired.
Expired drug patents of Xofigo are:
- US6635234
Xofigo was authorised for market use on 15 May, 2013.
Xofigo is available in solution;intravenous dosage forms.
Xofigo can be used as therapeutic treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease.
Drug patent challenges can be filed against Xofigo from 15 May, 2017.
The generics of Xofigo are possible to be released after 23 March, 2027.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 15, 2018 |
Drugs and Companies using RADIUM RA-223 DICHLORIDE ingredient
NCE-1 date: 15 May, 2017
Market Authorisation Date: 15 May, 2013
Treatment: Therapeutic treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease
Dosage: SOLUTION;INTRAVENOUS
XOFIGO family patents
